Itonic (NASDAQ:ITOC – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, FiscalAI reports. The company had revenue of $0.05 million for the quarter.
Itonic Stock Up 4.5%
Shares of Itonic stock opened at $0.28 on Thursday. The stock’s fifty day moving average is $0.29 and its two-hundred day moving average is $0.31. Itonic has a 52 week low of $0.22 and a 52 week high of $1.15.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings downgraded shares of Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.
Itonic Company Profile
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.
Featured Articles
- Five stocks we like better than Itonic
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
Receive News & Ratings for Itonic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Itonic and related companies with MarketBeat.com's FREE daily email newsletter.
